Literature DB >> 18370466

Erythropoietin effectiveness index : a quantitative definition of resistance in haemodialysis patients with adequate iron stores.

G R Bailie1, C L Low, G Eisele.   

Abstract

Entities:  

Year:  1998        PMID: 18370466     DOI: 10.2165/00044011-199815010-00007

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  10 in total

Review 1.  Iron management in end-stage renal disease.

Authors:  S Fishbane; J K Maesaka
Journal:  Am J Kidney Dis       Date:  1997-03       Impact factor: 8.860

2.  NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative.

Authors: 
Journal:  Am J Kidney Dis       Date:  1997-10       Impact factor: 8.860

Review 3.  Erythropoietin and iron.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Clin Nephrol       Date:  1997-03       Impact factor: 0.975

4.  High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients.

Authors:  P Bárány; J C Divino Filho; J Bergström
Journal:  Am J Kidney Dis       Date:  1997-04       Impact factor: 8.860

Review 5.  Poor response to erythropoietin: practical guidelines on investigation and management.

Authors:  I C Macdougall
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

6.  Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.

Authors:  F Sepandj; K Jindal; M West; D Hirsch
Journal:  Nephrol Dial Transplant       Date:  1996-02       Impact factor: 5.992

7.  Removal of iron dextran by hemodialysis: an in vitro study.

Authors:  R C Hatton; I T Portales; A Finlay; E A Ross
Journal:  Am J Kidney Dis       Date:  1995-08       Impact factor: 8.860

Review 8.  Evidence-based recommendations for the clinical use of recombinant human erythropoietin.

Authors:  N Muirhead; J Bargman; E Burgess; K K Jindal; A Levin; L Nolin; P Parfrey
Journal:  Am J Kidney Dis       Date:  1995-08       Impact factor: 8.860

9.  Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.

Authors:  S Fishbane; G L Frei; J Maesaka
Journal:  Am J Kidney Dis       Date:  1995-07       Impact factor: 8.860

Review 10.  Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration.

Authors:  A Besarab
Journal:  Am J Kidney Dis       Date:  1993-08       Impact factor: 8.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.